Karyopharm Therapeutics reported $61.76M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Amgen AMGN:US USD 14.33B 1.71B
AstraZeneca AZN:LN USD 24.85B 3.04B
Astrazeneca AZN:US USD 24.85B 3.04B
Avrobio Inc AVRO:US USD 16.19M 3.41M
Bristol Myers Squibb BMY:US USD 18.93B 1.98B
Eli Lilly And LLY:US USD 15.65B 32.2M
Enanta Pharmaceuticals ENTA:US USD 29.83M 6.79M
GlaxoSmithKline GSK:LN GBP 20.95B 16.88B
Karyopharm Therapeutics KPTI:US USD 61.76M 780K
Macrogenics MGNX:US USD 50.05M 831K
Mirati Therapeutics MRTX:US USD 126.99M 7.84M
Nektar Therapeutics NKTR:US USD 83.99M 21M
Novartis NOVN:VX USD 28.16B 514M
Novartis NVS:US USD 28.16B 514M
Regeneron Pharmaceuticals REGN:US USD 2.88B 154.7M
Roche Holding ROG:VX 27.41B 11.01B
Sangamo Biosciences SGMO:US USD 122.36M 2.37M
Takeda 4502:JP JPY 2.39T 224.78B
Tg Therapeutics TGTX:US USD 36.45M 6.88M
Ultragenyx Pharmaceutical RARE:US USD 227.36M 6.72M
Xencor XNCR:US USD 90.03M 14.99M
YTE INCY:US USD 1.01B 79.92M